6 Result(s)

Article

Urotensin II receptor antagonism confers vasoprotective effects in diabetes associated atherosclerosis: studies in humans and in a mouse model of diabetes

The small, highly conserved vasoactive peptide urotensin II (UII) is upregulated in atherosclerosis. However, its effects in diabetes-associated atherosclerosis have not been assessed.

A. M. D. Watson, M. Olukman, C. Koulis, Y. Tu, D. Samijono, D. Yuen, C. Lee… in Diabetologia (2013)

Article

Delayed intervention with AGE inhibitors attenuates the progression of diabetes-accelerated atherosclerosis in diabetic apolipoprotein E knockout mice

Formation of AGEs is increased in the diabetic milieu, which contributes to accelerated atherogenesis. We studied whether delayed treatment with AGE-inhibiting compounds, alagebrium chloride and pyridoxamine d...

A. M. D. Watson, A. Soro-Paavonen, K. Sheehy, J. Li, A. C. Calkin… in Diabetologia (2011)

Article

Cell division autoantigen 1 plays a profibrotic role by modulating downstream signalling of TGF-β in a murine diabetic model of atherosclerosis

Excess accumulation of vascular extracellular matrix (ECM) is an important pathological process in cardiovascular diseases including diabetes-associated atherosclerosis. We explored how a recently identified m...

Y. Pham, Y. Tu, T. Wu, T. J. Allen, A. C. Calkin, A. M. Watson, J. Li… in Diabetologia (2010)

Article

The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation

We evaluated the anti-atherosclerotic effect of the 3-hydroxy-3-methylglutaryl CoA reductase inhibitor, rosuvastatin, and the angiotensin II receptor blocker (ARB), candesartan, alone and in combination, in th...

A. C. Calkin, S. Giunti, K. J. Sheehy, C. Chew, V. Boolell, Y. S. Rajaram… in Diabetologia (2008)

Article

Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation

It is postulated that peroxisome proliferator-activated receptor α agonists confer cardiovascular benefits in diabetes, independently of their effects on lipid metabolism. We investigated putative mechanisms r...

A. C. Calkin, M. E. Cooper, K. A. Jandeleit-Dahm, T. J. Allen in Diabetologia (2006)

Article

40^th EASD Annual Meeting of the European Association for the Study of Diabetes

M. Veitenhansl, K. Stegner, F.-X. Hierl, C. Dieterle, H. Feldmeier, B. Gutt… in Diabetologia (2004)